Apogee Therapeutics price target raised to $130 from $89 at Canaccord

Canaccord analyst Edward Nash raised the firm’s price target on Apogee Therapeutics (APGE) to $130 from $89 and keeps a Buy rating on the shares. The firm raised its target following the release of positive 52-week maintenance results with Q3M and Q6M dosing from Part A of the Phase ll Apex study for zumilokibart (Zumi). Canaccord believes the results are very important for Apogee, since the data demonstrate strong proof-of-concept for the potential Q3M to Q6M dosing, which the firm views as the key differentiator for the drug from its peers in the IL-13 targeting class.